Abstract
Rheumatoid arthritis is an immune-mediated inflammatory disease of the synovium. Yet we still lack robust tissue-specific (synovial) biomarkers that are able to guide clinical decisions and stratify patients according to their disease subgroup and predicted response to treatment. The EULAR Synovitis Study Group and the OMERACT synovial tissue biopsy (STB) Special Interests Group have undertaken a consensus exercise to identify factors that are important for the standardisation of STB handling and analytical procedures in two situations - clinical practice and translational research.
Original language | English |
---|---|
Article number | 90 |
Journal | Arthritis Research & Therapy |
Volume | 21 |
DOIs | |
Publication status | Published - 8 Apr 2019 |
Bibliographical note
© The Author(s). 2019Open Access: This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Keywords
- synovial biopsy
- rheumatoid arthritis
- synovial tissue analysis
- standardisation
- fibroblast
- STB
- RA